Novocure PANOVA-4 trial meets primary endpoint; DCR 74.4% vs 48% historical control in mPDAC

NovoCure Ltd

PANOVA-4 met primary endpoint: DCR 74.4% (N=78) vs 48% historical control (N=431), 1-sided p<0.001.
Secondary endpoints: ORR 34.6% (95% CI 24.2%-46.2%), median OS 9.7 months (95% CI 7.9-12.7 months).
TTFields therapy with atezolizumab and gem/nab-pac well-tolerated; safety consistent with prior studies.
Novocure plans to present further PANOVA-4 data at a future scientific forum.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.